StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.40−0.05 (-10.74%)

Close on Nov 17, 2026Market cap $110.95MP/E –Yield –

Akebia Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Akebia Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $41.55M. For fiscal 2025 it was $67.99M. The highest annual figure on record is $67.99M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$67.99M–
FY2024Dec 31, 2024-$40.66M–
FY2023Dec 31, 2023-$23.38M–
FY2022Dec 31, 2022-$73.15M–
FY2021Dec 31, 2021-$252.97M–
FY2020Dec 31, 2020-$110.39M–
FY2019Dec 31, 2019-$257.44M–
FY2018Dec 31, 2018-$97.49M–
FY2017Dec 31, 2017-$56.16M-197.0%
FY2016Dec 31, 2016$57.91M–
FY2015Dec 31, 2015-$52.41M–
FY2014Dec 31, 2014-$27.48M–
FY2013Dec 31, 2013-$11.33M–
FY2012Dec 31, 2012-$7.21M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.53M-84.2%
Q1 FY2026Mar 31, 2026-$21.21M–
Q4 FY2025Dec 31, 2025$31.13M–
Q3 FY2025Sep 30, 2025$28.11M–
Q2 FY2025Jun 30, 2025$22.35M–
Q1 FY2025Mar 31, 2025-$13.59M–
Q4 FY2024Dec 31, 2024-$4.47M–
Q3 FY2024Sep 30, 2024-$6.70M–
Q2 FY2024Jun 30, 2024-$10.07M-377.4%
Q1 FY2024Mar 31, 2024-$19.43M–
Q4 FY2023Dec 31, 2023-$2.31M–
Q3 FY2023Sep 30, 2023-$7.17M-121.2%
Q2 FY2023Jun 30, 2023$3.63M–
Q1 FY2023Mar 31, 2023-$17.54M–
Q4 FY2022Dec 31, 2022-$54.68M–
Q3 FY2022Sep 30, 2022$33.81M–
Q2 FY2022Jun 30, 2022-$30.66M–
Q1 FY2022Mar 31, 2022-$21.62M–
Q4 FY2021Dec 31, 2021-$62.81M–
Q3 FY2021Sep 30, 2021-$56.27M–
Q2 FY2021Jun 30, 2021-$63.14M-269.6%
Q1 FY2021Mar 31, 2021-$70.75M–
Q4 FY2020Dec 31, 2020-$30.78M–
Q3 FY2020Sep 30, 2020-$27.24M-347.9%
Q2 FY2020Jun 30, 2020$37.22M–
Q1 FY2020Mar 31, 2020-$89.59M–
Q4 FY2019Dec 31, 2019-$92.14M–
Q3 FY2019Sep 30, 2019$10.99M–
Q2 FY2019Jun 30, 2019-$38.37M-526.5%
Q1 FY2019Mar 31, 2019-$137.93M–
Q4 FY2018Dec 31, 2018-$73.70M–
Q3 FY2018Sep 30, 2018-$12.46M–
Q2 FY2018Jun 30, 2018$9.00M-63.1%
Q1 FY2018Mar 31, 2018-$20.33M–
Q4 FY2017Dec 31, 2017-$16.38M-117.1%
Q3 FY2017Sep 30, 2017-$54.62M–
Q2 FY2017Jun 30, 2017$24.36M–
Q1 FY2017Mar 31, 2017-$9.53M–
Q4 FY2016Dec 31, 2016$95.67M–
Q3 FY2016Sep 30, 2016-$28.24M–

More Akebia Therapeutics figures

See a number that looks wrong?